Concepedia

Jörg Täubel

JT

43

Publications

4.5K

Citations

23

H-Index

2001

Active since

Affiliations

St George's, University of London(Current)

University College London

Alnylam Pharmaceuticals (United States)

Brigham and Women's Hospital

Georg Fischer (Switzerland)

Jörg Täubel is an author at St George's, University of London specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

2001–2024

43

Publications

43

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Julian D. Gillmore, Ed Gane, Jörg Täubel et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Kevin Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine · 2016 · 738 citations · Full text

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study

Jörg Täubel, Wilfried Hauke, Steffen Rump et al. · European Heart Journal · 2020 · 355 citations · Full text

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Marianna Fontana, John L. Berk, Julian D. Gillmore et al. · New England Journal of Medicine · 2024 · 286 citations · Full text

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Akshay S. Desai, David J. Webb, Jörg Täubel et al. · New England Journal of Medicine · 2023 · 232 citations · Full text

Rows per page

1–5 of 43